STUDY OF BONE DENSITY AND OSTEOCALCIN LEVEL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
(Abstract release date: 05/19/16)
EHA Library. Elsharkawy A. 06/09/16; 134516; PB1616
Dr. Asmaa Elsharkawy
Contributions
Contributions
Abstract
Abstract: PB1616
Type: Publication Only
Background
Leukemias are the most common malignant neoplasms in childhood, with acute lymphoblastic leukemia (ALL) accounting for 75% of all childhood leukemias and 30% of all childhood cancers. An increasing number of children survive ALL, approaching approximately 80% over the last 2 decades, as a result of improved and more intense chemotherapy. Musculoskeletal abnormalities are well recognized in children with ALL at diagnosis, during treatment, and persist as long-term sequelae after treatment. Osteotoxic chemotherapy, steroid exposure, poor nutrition, low vitamin D, and poor muscle mass contribute to the development or worsening of bone pathology during therapy that may result in osteoporosis, fracture, and osteonecrosis. Risk-directed therapy has substantially improved treatment outcomes for pediatric ALL, with 5-year survival rates approximating 80 % . Given success of this magnitude, it is important to address the management and prevention of bone toxicity. The current study evaluated the bone density and alterations in biochemical mineral status in children with ALL at time of diagnosis, during chemotherapy and after finishing chemotherapy.
Aims
To study Bone density and serum osteocalcin level in children with acute lymphoblastic leukemia.
Methods
Serum osteocalcin and DXA scan were evaluated in 45 children with ALL,15 at diagnosis and before starting chemotherapy, 15 during chemotherapy and 15 after completing their treatment regimen.
Results
From the total 45 patients, 23 (51.1%) had low osteocalcin level and 36 (80%) had low bone mineral density (48% had osteopenia and 32% had osteoporosis).
Conclusion
Musculoskeletal abnormalities are present in children with ALL at diagnosis, during treatment, and persist as long-term sequelae after treatment.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Bone Density
Type: Publication Only
Background
Leukemias are the most common malignant neoplasms in childhood, with acute lymphoblastic leukemia (ALL) accounting for 75% of all childhood leukemias and 30% of all childhood cancers. An increasing number of children survive ALL, approaching approximately 80% over the last 2 decades, as a result of improved and more intense chemotherapy. Musculoskeletal abnormalities are well recognized in children with ALL at diagnosis, during treatment, and persist as long-term sequelae after treatment. Osteotoxic chemotherapy, steroid exposure, poor nutrition, low vitamin D, and poor muscle mass contribute to the development or worsening of bone pathology during therapy that may result in osteoporosis, fracture, and osteonecrosis. Risk-directed therapy has substantially improved treatment outcomes for pediatric ALL, with 5-year survival rates approximating 80 % . Given success of this magnitude, it is important to address the management and prevention of bone toxicity. The current study evaluated the bone density and alterations in biochemical mineral status in children with ALL at time of diagnosis, during chemotherapy and after finishing chemotherapy.
Aims
To study Bone density and serum osteocalcin level in children with acute lymphoblastic leukemia.
Methods
Serum osteocalcin and DXA scan were evaluated in 45 children with ALL,15 at diagnosis and before starting chemotherapy, 15 during chemotherapy and 15 after completing their treatment regimen.
Results
From the total 45 patients, 23 (51.1%) had low osteocalcin level and 36 (80%) had low bone mineral density (48% had osteopenia and 32% had osteoporosis).
Conclusion
Musculoskeletal abnormalities are present in children with ALL at diagnosis, during treatment, and persist as long-term sequelae after treatment.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Bone Density
Abstract: PB1616
Type: Publication Only
Background
Leukemias are the most common malignant neoplasms in childhood, with acute lymphoblastic leukemia (ALL) accounting for 75% of all childhood leukemias and 30% of all childhood cancers. An increasing number of children survive ALL, approaching approximately 80% over the last 2 decades, as a result of improved and more intense chemotherapy. Musculoskeletal abnormalities are well recognized in children with ALL at diagnosis, during treatment, and persist as long-term sequelae after treatment. Osteotoxic chemotherapy, steroid exposure, poor nutrition, low vitamin D, and poor muscle mass contribute to the development or worsening of bone pathology during therapy that may result in osteoporosis, fracture, and osteonecrosis. Risk-directed therapy has substantially improved treatment outcomes for pediatric ALL, with 5-year survival rates approximating 80 % . Given success of this magnitude, it is important to address the management and prevention of bone toxicity. The current study evaluated the bone density and alterations in biochemical mineral status in children with ALL at time of diagnosis, during chemotherapy and after finishing chemotherapy.
Aims
To study Bone density and serum osteocalcin level in children with acute lymphoblastic leukemia.
Methods
Serum osteocalcin and DXA scan were evaluated in 45 children with ALL,15 at diagnosis and before starting chemotherapy, 15 during chemotherapy and 15 after completing their treatment regimen.
Results
From the total 45 patients, 23 (51.1%) had low osteocalcin level and 36 (80%) had low bone mineral density (48% had osteopenia and 32% had osteoporosis).
Conclusion
Musculoskeletal abnormalities are present in children with ALL at diagnosis, during treatment, and persist as long-term sequelae after treatment.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Bone Density
Type: Publication Only
Background
Leukemias are the most common malignant neoplasms in childhood, with acute lymphoblastic leukemia (ALL) accounting for 75% of all childhood leukemias and 30% of all childhood cancers. An increasing number of children survive ALL, approaching approximately 80% over the last 2 decades, as a result of improved and more intense chemotherapy. Musculoskeletal abnormalities are well recognized in children with ALL at diagnosis, during treatment, and persist as long-term sequelae after treatment. Osteotoxic chemotherapy, steroid exposure, poor nutrition, low vitamin D, and poor muscle mass contribute to the development or worsening of bone pathology during therapy that may result in osteoporosis, fracture, and osteonecrosis. Risk-directed therapy has substantially improved treatment outcomes for pediatric ALL, with 5-year survival rates approximating 80 % . Given success of this magnitude, it is important to address the management and prevention of bone toxicity. The current study evaluated the bone density and alterations in biochemical mineral status in children with ALL at time of diagnosis, during chemotherapy and after finishing chemotherapy.
Aims
To study Bone density and serum osteocalcin level in children with acute lymphoblastic leukemia.
Methods
Serum osteocalcin and DXA scan were evaluated in 45 children with ALL,15 at diagnosis and before starting chemotherapy, 15 during chemotherapy and 15 after completing their treatment regimen.
Results
From the total 45 patients, 23 (51.1%) had low osteocalcin level and 36 (80%) had low bone mineral density (48% had osteopenia and 32% had osteoporosis).
Conclusion
Musculoskeletal abnormalities are present in children with ALL at diagnosis, during treatment, and persist as long-term sequelae after treatment.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Bone Density
{{ help_message }}
{{filter}}